Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development

Oct 23 (Reuters) Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus ​AI to develop artificial intelligence tools ‌for drug development in Alzheimer s disease and other neurological disorders. Pathos AI also raised $237 million in a Series E funding round led by Bristol Myers that valued ‌the ​New York-based company at about $3 ⁠billion, with participation from ⁠existing investors. Here are some other details: • Tempus will build a dataset from hundreds of thousands of patients with neurological disorders to ​help track outcomes and speed research into disease biology • Pathos will license the data ⁠from Tempus under a five-year, $55 ⁠million agreement • Pathos will apply ​its AI platform, Pathos Foundry, to study the ​dataset at scale, generate and test hypotheses on ‌disease biology, and inform the design of more targeted, adaptive clinical trials • Bristol Myers will gain non-exclusive strategic access to Pathos Foundry ⁠across its bro